UBS Group’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-291,642
Closed -$24.8M 9156
2020
Q3
$24.8M Buy
291,642
+223,794
+330% +$11.3M 0.01% 1034
2020
Q2
$2.4M Buy
67,848
+27,647
+69% +$808K ﹤0.01% 2701
2020
Q1
$542K Sell
40,201
-132,778
-77% -$2.23M ﹤0.01% 3893
2019
Q4
$3.66M Sell
172,979
-239,682
-58% -$4.23M ﹤0.01% 2907
2019
Q3
$5.47M Buy
412,661
+231,639
+128% +$3.41M ﹤0.01% 2301
2019
Q2
$2.51M Buy
181,022
+174,477
+2,666% +$2.63M ﹤0.01% 2943
2019
Q1
$125K Sell
6,545
-105,608
-94% -$1.7M ﹤0.01% 4922
2018
Q4
$1.6M Buy
112,153
+58,927
+111% +$1.17M ﹤0.01% 3258
2018
Q3
$1.11M Buy
53,226
+43,775
+463% +$1.04M ﹤0.01% 3744
2018
Q2
$224K Sell
9,451
-179,779
-95% -$3.61M ﹤0.01% 4860
2018
Q1
$2.77M Sell
189,230
-170,740
-47% -$2.79M ﹤0.01% 2849
2017
Q4
$5.82M Buy
359,970
+45,495
+14% +$537K ﹤0.01% 2204
2017
Q3
$4.4M Buy
314,475
+244,311
+348% +$2.43M ﹤0.01% 2331
2017
Q2
$620K Buy
70,164
+66,464
+1,796% +$467K ﹤0.01% 3970
2017
Q1
$24K Buy
3,700
+1,000
+37% +$5.07K ﹤0.01% 6028
2016
Q4
$10K Hold
2,700
﹤0.01% 6942
2016
Q3
$9K Sell
2,700
-21,292
-89% -$59.5K ﹤0.01% 6867
2016
Q2
$56K Buy
23,992
+11,903
+98% +$39.8K ﹤0.01% 5442
2016
Q1
$30K Sell
12,089
-9,574
-44% -$21.5K ﹤0.01% 5902
2015
Q4
$66K Buy
21,663
+10,413
+93% +$29.1K ﹤0.01% 5578
2015
Q3
$19K Sell
11,250
-10,640
-49% -$27.2K ﹤0.01% 6763
2015
Q2
$89K Hold
21,890
﹤0.01% 5497
2015
Q1
$84K Sell
21,890
-7,190
-25% -$31.3K ﹤0.01% 5565
2014
Q4
$140K Buy
+29,080
New +$115K ﹤0.01% 5356

UBS Group's IMMU Position: Q4 2020 in Review

UBS Group sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 291,642 shares — an estimated $24.8M sold.

UBS Group first reported a position in IMMU in Q4 2014 and held it in 24 quarters. The position peaked at $24.8M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • UBS Group reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • UBS Group sold 291,642 Immunomedics Inc shares in Q4 2020, an estimated $24.8M.
  • UBS Group first reported a position in Immunomedics Inc in Q4 2014 and held it in 24 quarters.
  • UBS Group's Immunomedics Inc position peaked at $24.8M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on UBS Group's 13F filing for Q4 2020, filed 11 Feb 2021.